Hara M, Nakamura T, Fujii Y
Gan To Kagaku Ryoho. 1987 May;14(5 Pt 1):1338-41.
Six patients with multiple myeloma were treated with HLBI-MP regimen; HLBI 300 X 10(4)U/day daily, Melphalan 4 mg/day p.o. from day 1 to 4 and prednisolone 20 mg/day p.o. from day 1 to 4. Two patients had been refractory to a combination chemotherapy consisting of vincristine, cyclophosphamide, prednisolone and/or adriamycin, while the other 4 patients had been previously untreated. With the HLBI-MP regimen, 3 of 6 patients showed clinical effects. Among the two patients previously treated, one showed an improvement in performance status and the other disappearance of plasmacytoma, respectively. One previously untreated patient showed more than 50% reduction of M-protein. Slight to moderate leukocytopenia was found in all cases, but this was controlled without need for cessation of HLBI. HLBI-MP regimen is thus expected to be useful in the clinical management of patients with multiple myeloma.
6例多发性骨髓瘤患者接受HLBI-MP方案治疗；HLBI 300×10⁴U/天，静脉滴注，美法仑4mg/天，口服，第1至4天，泼尼松龙20mg/天，口服，第1至4天。2例患者对由长春新碱、环磷酰胺、泼尼松龙和/或阿霉素组成的联合化疗耐药，而其他4例患者此前未接受过治疗。采用HLBI-MP方案治疗后，6例患者中有3例显示出临床疗效。在2例先前接受过治疗的患者中，1例患者的体能状态有所改善，另1例患者的浆细胞瘤消失。1例先前未接受过治疗的患者M蛋白减少超过50%。所有病例均出现轻度至中度白细胞减少，但无需停用HLBI即可得到控制。因此，HLBI-MP方案有望在多发性骨髓瘤患者的临床管理中发挥作用。
